Beyond L'Oréal: the Second Wave of Hair Relaxer Defendants Now in Discovery — and the September 2027 Trial Date
A second group of hair-relaxer manufacturers is now moving through discovery in the federal hair-relaxer litigation, while the first bellwether trial, against L'Oréal USA, is set for September 7, 2027. No settlement exists yet, no verdict has been returned in this litigation, and no per-claimant payment figure exists — so anyone quoting one is guessing.
- 12,381 cases were pending in MDL 3060 as of the October 1, 2026 Judicial Panel report, with 16,828 filed since consolidation.
- The bellwether pool narrowed from 32 cases to 10 in July 2026, and then to 5 cases, with the first trial set for September 7, 2027.
- The September 24, 2026 court order also set monthly status conferences from January 28, 2027 until trial, with expert discovery for the five pool cases closing December 21, 2026.
- The second wave of defendants named in discovery includes Wella, John Paul Mitchell Systems, Bronner Bros., Dudley Beauty Corp., Murray's Worldwide, and Advanced Beauty.
- Arizona's September 2026 suit against L'Oréal USA is a state enforcement action: it seeks consumer relief and warnings, but it pays individual claimants nothing.
For plain-language explainers on related legal topics, the Problem Solved channel publishes guides that help readers understand their options before they act.
What the second wave actually is
Most coverage names one defendant, L'Oréal USA, because the first federal bellwether trial is set against it — but that picture is incomplete. A multidistrict litigation, or MDL, gathers similar federal cases before one judge for pretrial work, and this one, MDL 3060 in the Northern District of Illinois before Judge Rowland, has always contained more than one manufacturer. The cases allege that chemical hair relaxers and straighteners, used regularly over years, increased the risk of uterine, endometrial, and ovarian cancers, and that the companies failed to warn users. The companies dispute causation and liability.
The second wave is the litigation's next layer. While the bellwether cases against the first group of defendants move toward trial, a second set of manufacturers — including Wella, John Paul Mitchell Systems, Bronner Bros., Dudley Beauty Corp., Murray's Worldwide, and Advanced Beauty — is moving forward with discovery, the stage in which each side must hand over documents, answer questions, and sit for depositions. Discovery is not a finding of fault; it is the work that decides whether a claim can be proved: what the company knew, what it told consumers, and what its testing showed. For women whose relaxer brand was not L'Oréal, this wave is the part of the case that concerns them.
As of October 2026 there is no global hair-relaxer settlement, no settlement matrix, and no verdict in MDL 3060, though a court-appointed special master continues to facilitate settlement discussions in parallel.
How the trial pool was narrowed to five
A bellwether trial is a test case. The court and the parties select a small number of representative cases to try first, because their outcomes — and the rulings on expert evidence along the way — tell both sides how juries respond to the science and what a broader resolution might look like. A bellwether verdict binds only the plaintiff in that case, but it shapes every negotiation that follows.
In July 2026 Judge Rowland narrowed the bellwether pool from 32 cases to 10. By October the pool had narrowed again, to 5 cases, and on September 24, 2026 the court ordered the first of them to trial on September 7, 2027. Expert discovery for those five cases closes December 21, 2026, and the court set monthly status conferences from January 28, 2027 until trial. This is the first court-ordered trial date in the litigation, superseding earlier reports of a January 2027 trial that was never ordered.
The schedule also explains the long silence between now and trial. Before any jury hears a case, the court must rule on Daubert motions, the challenges to whether each side's expert testimony is scientifically reliable enough to be admitted. In a case built on epidemiology, those rulings are decisive: excluded causation experts collapse cases before trial, admitted ones raise settlement pressure sharply.
What Arizona's case does, and what it does not do
In September 2026 Arizona's attorney general sued L'Oréal USA under the Arizona Consumer Fraud Act over its Dark & Lovely, Optimum, and Mizani relaxer lines, alleging the company created a false impression that the products were safe and seeking consumer relief and warnings on future sales. Our separate account explains why Arizona sued L’Oréal over hair relaxers in September 2026 — and why that suit, on its own, pays individual claimants nothing.
The two tracks are easily confused. The Arizona suit is a state enforcement action: the state is the plaintiff, and any relief goes to consumers generally, not to women holding MDL claims. It is not part of MDL 3060. Its value to MDL plaintiffs is indirect: a state attorney general building a concealment case works from the same internal documents and epidemiology the MDL plaintiffs are litigating.
On the regulatory side, the Food and Drug Administration proposed a formaldehyde ban in hair relaxers in October 2023 but missed its April 2024 deadline, and no federal ban has followed, while California banned formaldehyde in cosmetics as of January 2025. None of that decides any individual case, but it frames the warning question at the heart of the claims.
Who Benefits From This — and Who Does Not
Women with a qualifying diagnosis and a documented history of regular relaxer use are the people this litigation is built for. The strongest profiles are women diagnosed with uterine, endometrial, or ovarian cancer after years of frequent use of chemical relaxers, who can name the products they used and roughly when. Women who used relaxers for a decade or more and kept even partial records are better positioned than women whose use was brief or undocumented. Salon workers form a distinct group: stylists who applied relaxers daily for years may have the most sustained exposure of anyone, and the occupational exposure claims most stylists miss deserve separate attention.
Who does not benefit is equally clear. Women who used relaxers but never developed a qualifying diagnosis do not have an injury claim in this litigation, however strong their concern about past use. Women whose only diagnosis is uterine fibroids without a hysterectomy generally proceed, if at all, through state court programs rather than the federal MDL, and the rules there differ. And anyone expecting a payment from the Arizona enforcement suit, or from a settlement fund that does not yet exist, will be disappointed: as of October 2026 there is nothing to claim from, only cases to file and a trial calendar to watch. Our October 2026 update tracks the case count and trial date.
A final group deserves honesty: women whose diagnosis came many years ago and who never investigated a claim. Deadlines vary by state and often run from discovery of the possible connection; examples reported for states following this MDL include generally three years in North Carolina and two years in Georgia and Alabama. If you think you may qualify, a legal review now preserves options that delay destroys.
The proof that decides a claim
Proof is assembled from ordinary records, above all the product history: brand names, purchase records, salon receipts, photographs, and testimony from family or stylists who remember what was used and how often. Medical records matter in parallel — diagnosis, pathology, treatment — because the claim requires both exposure and a qualifying disease, connected by expert science. Gaps in either chain are where defense lawyers attack.
Women without salon records are not out of options: pharmacy and retail purchase histories, loyalty records, photographs, and consistent witness accounts can reconstruct years of use. What cannot be reconstructed is time, so preserve what you have now and get a review before a deadline decides the question for you.
What to watch between now and September 2027
Three dates structure the next year: expert discovery for the five bellwether cases closes December 21, 2026, monthly status conferences run from January 28, 2027 until trial, and the first bellwether trial opens September 7, 2027.
No outcome guarantees a settlement: a bellwether win would price the litigation, not end it. A plaintiff verdict would pressure every defendant, including the second wave; a defense verdict would do the opposite. Either way, the women who benefit most will be those already filed and documented when the first verdict lands.
Frequently asked questions
Who benefits most from the hair relaxer litigation?
Women diagnosed with uterine, endometrial, or ovarian cancer after years of regular chemical relaxer use, who can document the products they used, and salon workers with sustained occupational exposure to relaxers.
Who does not benefit, or who is not eligible?
Women who used relaxers but never developed a qualifying diagnosis have no injury claim in this litigation, and women whose only diagnosis is fibroids without hysterectomy generally proceed through state programs rather than the federal MDL. No one benefits from the Arizona enforcement suit directly, because it pays individual claimants nothing.
How do I start a hair relaxer claim?
Write down every relaxer brand you used, with years and frequency; gather receipts, photographs, and witness accounts; collect your diagnosis and treatment records; then get a legal review promptly, because deadlines often run from discovery of the possible connection.
Does Arizona's lawsuit against L'Oréal pay me anything?
No. It is a state enforcement action seeking consumer relief and warnings on future sales. It is not part of MDL 3060 and does not pay individual claimants, though documents it produces could help the MDL cases.
What does the second wave of defendants mean for my claim?
It means the litigation extends beyond L'Oréal: brands by Wella, John Paul Mitchell Systems, Bronner Bros., Dudley Beauty, Murray's Worldwide, or Advanced Beauty sit in the discovery wave now moving forward, not in the first bellwether trial.
When will anyone actually be paid in this litigation?
No one can say yet: there is no settlement, verdict, or payment matrix as of October 2026, and any timeline would follow the September 7, 2027 trial and later negotiations.
This article provides general information only and is not legal advice. For advice about your specific situation, consult a qualified attorney.